| Enzo Biochem has entered into an agreement with GeneNews, of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey. Enzo will undertake to validate and seek approval of the ColonSentry test pursuant to New York, New Jersey and Clinical Laboratory Improvement Act requirements, in addition to marketing, and securing third party reimbursement for the test. Terms were not disclosed. Enzo said that subject to regulatory and reimbursement approval, among others, it hopes to make the test available in the second half of 2010. The test offers a novel, non-invasive option for determining an individual’s current risk for colorectal cancer and helps prioritize patients at greater risk for the disease. :theflyonthewall.com |
Subscribe for More Information